$3.59▴ 0.28%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-0.45cash per $1 profit
Weak
Much of its reported profit is not backed by operating cash.
Valuation
79th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+6.9%year over year
Decelerating
Growth is positive but slowing.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Nephros, Inc. turns -45¢ of every reported profit-dollar into real cash. Much of its reported profit is not backed by operating cash. Growth is positive but slowing. Its valuation sits in the richer end of its own recent range.
Key numbers
Valuation
EPS (TTM)$0.07
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin4.1%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$19.12M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.